Amino.Desk

Eloralintide

Updated Nov 17, 2026 · Clinical review: pending

Eloralintide is an experimental once-weekly injection from Eli Lilly that acts on the amylin receptor, a different target from the GLP-1 drugs. A mid-stage trial showed weight loss of up to about 20%. It is in Phase 3 trials and cannot be prescribed.

What it is

Amylin is a hormone released with insulin that helps produce the feeling of fullness. Eloralintide is a selective amylin receptor agonist, formerly known as LY3841136. It belongs to the same new class as cagrilintide.

What the evidence shows

The Phase 2 trial enrolled 263 adults with obesity, or overweight with a related condition, and without type 2 diabetes. At 48 weeks, average weight loss ranged from 9.5% on the lowest dose to 20.1% on the highest, against 0.4% on placebo. Lilly presented the results in November 2025.

In September 2026 Lilly reported that eloralintide combined with tirzepatide produced more weight loss than tirzepatide alone in a 48-week trial in adults with obesity and type 2 diabetes.

These are company-reported mid-stage results. Phase 3 trials, which are larger and longer, decide whether the effect and the safety hold up.

Legal status

Reported dosing

No approved dose exists.

The Phase 2 trial tested 1 mg, 3 mg, 6 mg and 9 mg once a week, and two schedules that stepped up to 9 mg. Those are trial doses in a monitored study, not a recommendation.

Safety

Common questions

Is eloralintide FDA-approved?

No. It is in Phase 3 trials.

How much weight did people lose on eloralintide?

Between 9.5% and 20.1% at 48 weeks in the Phase 2 trial, depending on dose, against 0.4% on placebo.

How is eloralintide different from a GLP-1?

It acts on the amylin receptor, a separate fullness signal.

Can I get eloralintide now?

Only by taking part in a clinical trial.

Ask an AI about this page

Opens the assistant with a question about this page already typed in. You can edit it before sending.

Ask ChatGPTAsk ClaudeAsk Perplexity

These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.

Sources

Free field guide

Forty peptides and GLP-1s: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy